Tenax Therapeutics Inc.
Organization details
- Legal name
- Tenax Therapeutics Inc.
- Former names
- Oxygen Biotherapeutics, INC. Synthetic Blood International Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Chapel Hill
- Headquarters state / province
- North Carolina
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TENX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000034956
- EIN
- 26-2593535
Board of directors
-
Christopher Thomas Giordano · Director · CEOSince 2024
-
Declan Doogan · DirectorSince 2024
-
Gerald T. Proehl · DirectorSince 2024
-
June Sherie Almenoff · DirectorSince 2024
-
Michael H. Davidson · DirectorSince 2024
-
Robyn Hunter · DirectorSince 2024
-
Stuart Rich · Director · Chief Medical OfficerSince 2024
Chief executives
Director election results
Annual meeting of June 2, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
89.7%
-
98.8%
-
99.0%
-
99.0%
-
99.0%
-
99.0%
-
99.0%
Board connections
3 of this board's directors also sit on 6 other boards. 6 are in the same sector.
-
Actinium Pharmaceuticals Inc. (Delaware) Same sectorvia June Sherie Almenoff
-
Avalo Therapeutics Inc. Same sectorvia June Sherie Almenoff
-
BioAge Labs Inc. Same sectorvia Michael H. Davidson
-
Dermata Therapeutics Inc. Same sectorvia Gerald T. Proehl
-
NewAmsterdam Pharma Company N.V. Same sectorvia Michael H. Davidson
- via Michael H. Davidson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $6,586,081
- 27 purchases by 8 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 21, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +331,979 | $1.66 | $550,687 |
| Oct 20, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +254,342 | $1.60 | $405,726 |
| Oct 19, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +336,528 | $1.51 | $507,013 |
| Sep 16, 2026 | Declan Doogan Director | Open-market purchase | +53,000 | $1.92 | $101,760 |
| Sep 15, 2026 | Christopher Thomas Giordano Director, Officer (CEO) | Open-market purchase | +4,850 | $1.82 | $8,827 |
| Sep 11, 2026 | Christopher Thomas Giordano Director, Officer (CEO) | Open-market purchase | +6,000 | $1.88 | $11,280 |
| Sep 11, 2026 | STAAB THOMAS R II Officer (Chief Financial Officer) | Open-market purchase | +5,675 | $1.94 | $11,010 |
| Sep 3, 2026 | ADAR1 Capital Management, LLC 10% owner | Open-market purchase | +900,000 | $1.78 | $1,602,000 |
| Sep 2, 2026 | Schneeberger Daniel 10% owner | Open-market purchase | +187,704 | $1.80 | $337,867 |
| Sep 1, 2026 | Schneeberger Daniel 10% owner | Open-market purchase | +179,058 | $1.80 | $322,304 |
| Aug 31, 2026 | Schneeberger Daniel 10% owner | Open-market purchase | +403,571 | $1.79 | $722,392 |
| Aug 24, 2026 | Schneeberger Daniel 10% owner | Open-market purchase | +107,374 | $1.75 | $187,905 |
| Aug 21, 2026 | Schneeberger Daniel 10% owner | Open-market purchase | +716,369 | $1.77 | $1,267,973 |
| Aug 20, 2026 | Schneeberger Daniel 10% owner | Open-market purchase | +202,124 | $1.78 | $359,781 |
| Jul 13, 2026 | Christopher Thomas Giordano Director, Officer (CEO) | Option exercise | +219 | $3.55 | $777 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Tenax Therapeutics Inc.
Who is the CEO of Tenax Therapeutics Inc.?
Christopher Thomas Giordano is Tenax Therapeutics Inc.'s CEO.
How many directors are on Tenax Therapeutics Inc.'s board?
Tenax Therapeutics Inc.'s board has 7 directors: Christopher Thomas Giordano, Declan Doogan, Gerald T. Proehl, June Sherie Almenoff, Michael H. Davidson, Robyn Hunter and Stuart Rich.
Are Tenax Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Tenax Therapeutics Inc. insiders bought $6.6 million of shares in 27 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="tenax-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.